Warning letters, 483s, Recalls, Import Alerts, Audit observations
USFDA Inspection of Pharmathen’s Rodopi facility in Greece (FEI 3009961173) resulted in issuance of Form
The USFDA has classified Sun Pharma’s Baska (Halol) facility (FEI: 3002957541) as Official Action Indicated
Novo Nordisk owned Catalent Indiana sterile products formulation facility was inspected by USFDA in June
The FDA inspected Colgate-Palmolive/Tom’s of Maine, Inc’s Sanford facility in the US in May 2024.
The USFDA issued a warning letter in January 2025 to Sanofi’s API facility in Framingham,
Indoco Remedies’ Goa Plant (FEI 3005124189) received a warning letter from the FDA following critical
The USFDA has issued a Warning Letter to Hyderabad-based OTC manufacturer Akron Formulations for critical
Aurobindo arm Eugia Pharma site at Sangareddy, Telengana was inspected by USFDA in Jan -Feb
Sun Pharma initiated recall of several drugs manufactured at Dadra site (India) for cGMP deviation
FDA had issued USFDA 483 in December 2022 to Novartis US site at Morris Plains,
